野村研究报告指,基于药明康德(02359.HK) 公布的盈喜,料2025年第四季收入将按年增长9.2%至117亿元人民币(下同),净利润增长142%至71亿元。展望2026财年,预期公司收入将按年增长16%至526亿元,高于市场预期的511亿元,因化学业务表现强劲;盈利则按年增长3%至196亿元。持续经营业务的按年增长率为21%。按业务划分,该行预期2026财年TIDES及后期发展与制造业务收入将...
Source Link野村研究报告指,基于药明康德(02359.HK) 公布的盈喜,料2025年第四季收入将按年增长9.2%至117亿元人民币(下同),净利润增长142%至71亿元。展望2026财年,预期公司收入将按年增长16%至526亿元,高于市场预期的511亿元,因化学业务表现强劲;盈利则按年增长3%至196亿元。持续经营业务的按年增长率为21%。按业务划分,该行预期2026财年TIDES及后期发展与制造业务收入将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.